Skip to Content

Join the 'Breast Cancer - Adjuvant' group to help and get support from people like you.

Breast Cancer - Adjuvant News

Lynparza (Olaparib), First Treatment Approved for Breast Cancer Caused by Specific Gene Mutation

Posted 4 days ago by Drugs.com

FRIDAY, Jan. 12, 2018 – Lynparza (olaparib) has been approved by the U.S. Food and Drug Administration to treat spreading breast cancer caused by a BRCA gene mutation. The drug is among a class called poly ADP-ribose polymerase (PARP) inhibitors, which are designed to block an enzyme involved in repairing damaged DNA. The hope is that by blocking the repair of cancer cells, the cells will die and slow or stop tumor growth, the FDA said in a news release Friday. "This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence. "This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of cancer, often across cancer types." More than 250,000 women in the United ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Lynparza, Olaparib

Dissatisfaction With Breasts May Mean Fewer Self-Checks for Cancer

Posted 6 days ago by Drugs.com

WEDNESDAY, Jan. 10, 2018 – Women who are unhappy with the size of their breasts – whether too big or too small – may be less likely to perform self-exams to check for signs of breast cancer, new research suggests. These women are also more likely to put off seeing a doctor if they do find a suspicious lump in their breast, the study found. "For women who are dissatisfied with their breast size, having to inspect their breasts may be experienced as a threat to their body image and so they may engage in avoidance behaviors," said study co-author Viren Swami. He's a social psychology professor at Anglia Ruskin University in Cambridge, England. "Breast size dissatisfaction may also activate negative self-conscious emotions such as shame and embarrassment that results in avoiding breast self-examination," Swami said in a university news release. Most of the 384 women in the study admitted ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative

FDA Approves Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer

Posted 7 days ago by Drugs.com

South San Francisco, CA – December 20, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (EBC) at high risk of recurrence. People should receive the adjuvant Perjeta-based regimen for one year (up to 18 cycles). The FDA has also converted the previously granted accelerated approval of the Perjeta-based regimen to full approval for neoadjuvant (before surgery) treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than two centimeters in diameter or node-positive). People receiving the neoadjuvant Perjeta-based regimen should continue Perjeta and H ... Read more

Related support groups: Breast Cancer, Breast Cancer - Adjuvant, Perjeta, Pertuzumab

Many With Early Breast Cancer Are Skipping Chemo

Posted 14 Dec 2017 by Drugs.com

WEDNESDAY, Dec. 13, 2017 – Fewer women with early stage breast cancer are turning to chemotherapy to fight their disease, a new study finds. "For patients with early stage breast cancer, we've seen a significant decline in chemotherapy use over the last few years without a real change in evidence," said study author Dr. Allison Kurian. She's an associate professor of medicine and of health research and policy at Stanford University. "This likely reflects a change in the culture of how physicians are practicing, and a move toward using tumor biology to guide treatment choices rather than solely relying on clinical measures," Kurian said in a Stanford news release. "We believe this study indicates that physicians are attempting to be more selective in their recommendations and to spare patients toxicity when possible," she said. The researchers looked at nearly 3,000 women treated for ... Read more

Related support groups: Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer, Prevention

For Breast Cancer Patients, Less Time on Hormonal Meds?

Posted 7 Dec 2017 by Drugs.com

THURSDAY, Dec. 7, 2017 – Women with earlier-stage breast cancer may be able to spend less time on hormonal therapy without dimming their prognosis, a new study suggests. In a trial of nearly 3,500 patients, researchers found that seven years of hormonal therapy was as effective as 10 years. By the study's end, more than three-quarters of women in both groups were alive and recurrence-free. The results are "important," according to experts attending the San Antonio Breast Cancer Symposium, where the study was released Thursday. "Potentially, there is a large group of patients who don't need 10 years of therapy," said Dr. Susan Domchek, of the University of Pennsylvania's Abramson Cancer Center. Domchek, who was not involved in the study, said decisions around hormonal therapy are often a source of "major discussion and angst" for patients and doctors. Hormonal therapy involves drugs ... Read more

Related support groups: Breast Cancer, Tamoxifen, Arimidex, Femara, Anastrozole, Letrozole, Aromasin, Breast Cancer - Adjuvant, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Tamoxifen Hexal, Tamosin, Nolvadex, Testolactone, Soltamox, Tamone, Emblon, Tamoxen, Genox

Acupuncture May Ease Pain Tied to Breast Cancer Care

Posted 7 Dec 2017 by Drugs.com

THURSDAY, Dec. 7, 2017 – Some common breast cancer medications can trigger joint pain, but new research suggests acupuncture may ease that side effect. The finding could be a win-win for breast cancer patients, said one oncologist who reviewed the study. "Acupuncture has been around for thousands of years and has no real downside," said Dr. Lauren Cassell, chief of breast surgery at Lenox Hill Hospital in New York City. "If something so simple as acupuncture can improve upon these symptoms and the patients' quality of life, we will have more women becoming compliant in taking their medication, and one would expect improved outcomes," Cassell added. The new study was led by Dr. Dawn Hershman, who heads the Breast Cancer Program at NewYork-Presbyterian/Columbia University Medical Center, also in New York City. Hershman's team tracked outcomes for 226 postmenopausal women with early stage ... Read more

Related support groups: Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative

New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too

Posted 7 Dec 2017 by Drugs.com

WEDNESDAY, Dec. 6, 2017 – Adding a new drug to standard treatment can slow the progression of advanced breast cancer in younger women, a new clinical trial has found. The drug, called ribociclib (Kisqali), was approved by the U.S. Food and Drug Administration in March for the treatment of postmenopausal women with advanced breast cancer. Now, experts say, the drug is just as effective for premenopausal women. In the trial, the treatment typically doubled the time a woman remained free of cancer progression – from roughly one year to two years. That benefit is "strikingly similar" to what's been seen in postmenopausal women, said Dr. Neil Iyengar, who specializes in treating breast cancer at Memorial Sloan Kettering Cancer Center in New York City. Breast cancer occurs most often in older women, and tumors that develop before menopause tend to be more aggressive, explained Iyengar. ... Read more

Related support groups: Breast Cancer, Tamoxifen, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Kisqali, Tamoxifen Hexal, Genox, Nolvadex D, Tamofen, Tamosin, Ribociclib, Emblon, Letrozole/ribociclib, Nolvadex, Soltamox, Tamone, Tamoxen

Risk of Breast Cancer's Return Can Linger for Decades

Posted 8 Nov 2017 by Drugs.com

WEDNESDAY, Nov. 8, 2017 – Women treated for early stage breast cancer still face a substantial risk of recurrence up to 20 years later, a large, new study shows. Cancer experts say the findings should help inform women's treatment decisions. Specifically, the researchers followed women with estrogen-receptor-positive breast cancer, which means the hormone helps fuel the cancer's growth. Standard treatment includes hormonal therapy – with drugs that block estrogen's effects – to help prevent a return of the cancer. All of the women in the study, nearly 63,000, were scheduled to receive the typical five years of hormonal therapy. Researchers found that while the women remained cancer-free for those five years, the risk for recurrence over the next 15 years was still significant. It was greatest for women whose initial cancer had spread to multiple lymph nodes near the breast by the ... Read more

Related support groups: Cancer, Breast Cancer, Tamoxifen, Arimidex, Anastrozole, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Tamoxifen Hexal, Emblon, Nolvadex, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin

Why Many Breast Cancer Patients Short-Circuit Their Treatment

Posted 7 Nov 2017 by Drugs.com

MONDAY, Nov. 6, 2017 – Many breast cancer patients skip recommended treatment after surgery because they lack faith in the health care system, a new study indicates. A patient survey found those who reported a general distrust of medical institutions and insurers were more likely to forgo follow-up breast cancer treatment, such as chemotherapy, hormone therapy or radiation. Trust or distrust of their own doctors did not emerge as a factor. "If we want more women with breast cancer to complete their treatment, we'll need to deal with their beliefs about the health care system – and I do think we can modify those beliefs," said study lead author Lorraine Dean. She's an assistant professor of epidemiology at Johns Hopkins University. Dean's team surveyed more than 2,700 patients in Florida and Pennsylvania after breast cancer surgery. More than 30 percent disregarded their doctor's ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Even Advanced Breast Cancer Patients Gain From Exercise

Posted 2 Nov 2017 by Drugs.com

THURSDAY, Nov. 2, 2017 – For women with advanced breast cancer, a well-planned exercise program might have a big impact on their quality of life, a small study suggests. Though cancer treatment can extend the lives of women with advanced breast cancer, many patients experience pain, fatigue and a reduced ability to carry out normal daily activities. The study involved 15 women, aged 34 to 68, who were undergoing treatment for advanced breast cancer and were not exercising. Seven continued to receive normal care, and eight were assigned to a 12-week exercise program that included an hour of exercise twice a week, including aerobic and resistance training. Compared with those in the normal-care group, women who exercised showed significant improvements in heart health, pain, fatigue, emotional well-being and the ability to do daily tasks. "This is a small group of patients, but the ... Read more

Related support groups: Fatigue, Breast Cancer, Prevention of Cardiovascular Disease, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Cardiovascular Risk Reduction, Breast Cancer - Palliative

Many High-Risk Women Skip MRI Breast Cancer Screenings

Posted 26 Oct 2017 by Drugs.com

THURSDAY, Oct. 26, 2017 – Knowing they're at increased risk for breast cancer isn't enough to persuade many women to get MRI screenings – even if they're free. Researchers studied more than 1,000 women in a U.S. military health system who had a 20 percent or greater lifetime risk of breast cancer due to genetics or personal or family history. Between 2015 and 2016, they were offered free MRI cancer screening at the Madigan Army Medical Center in Tacoma, Wash. (Women with higher than average risk are advised to start annual MRIs and mammograms at age 30, according to the American Cancer Society.) But only 23 percent of the women underwent MRI screening. That included 15 percent of those with a 20 to 24 percent lifetime risk of breast cancer, and only half of those with more than a 40 percent risk. The study was to be presented Wednesday at an American College of Surgeons meeting in San ... Read more

Related support groups: Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Diagnosis and Investigation, Body Imaging

Joan Lunden's Breast Cancer Journey: 'You Feel So Vulnerable'

Posted 26 Oct 2017 by Drugs.com

THURSDAY, Oct. 26, 2017 – Joan Lunden – co-host of "Good Morning America" for nearly two decades and a long-time health advocate – is now also a breast cancer survivor. By sharing her experience, Lunden hopes she can help other women facing a frightening cancer diagnosis. "It's so shocking when you hear you have cancer, and you feel so vulnerable," said Lunden, 67. Lunden never missed an annual mammogram to check for breast cancer. But each year, she said the process was "nerve-racking" because she has dense breast tissue that can make it difficult to distinguish healthy breast tissue from tumor tissue. Many women with dense breast tissue, particularly those with risk factors for breast cancer such as a family history, are advised to get additional testing – an MRI or sometimes an ultrasound. When Lunden went in for an ultrasound, she received shocking news. "I had an aggressive, ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation, Body Imaging

Textured Breast Implants Linked to Rare Cancer

Posted 20 Oct 2017 by Drugs.com

FRIDAY, Oct. 20, 2017 – A particular breast implant may be associated with a rare type of cancer, researchers report. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is estimated to affect 1 in 30,000 women each year, but researchers said it may actually be more common. "We're seeing that this cancer is likely very underreported, and as more information on this type of cancer comes to light, the number of cases is likely to increase in the coming years," said Dr. Dino Ravnic. He is an assistant professor of surgery at Penn State College of Medicine. Penn State investigators reviewed 115 research reports in which 95 patients were evaluated to learn more about risk, development and treatment of BIA-ALCL. Nearly all cases were associated with textured breast implants, which have a slightly rough surface to keep them in the correct position. "We're still exploring the ... Read more

Related support groups: Surgery, Breast Cancer, Lymphoma, Breast Cancer - Adjuvant, Breast Cancer, Prevention

Breast Cancer More Lethal for Blacks Than Whites

Posted 16 Oct 2017 by Drugs.com

MONDAY, Oct. 16, 2017 – Differences in insurance are a major reason why black women are more likely to die of breast cancer than white women in the United States, a new study contends. "We found that differences in insurance explained one-third of the total excess risk of death in non-elderly black women compared to white women diagnosed with early stage breast cancer, while differences in tumor characteristics explained approximately one-fifth of the excess risk," lead study author Ahmedin Jemal, of the American Cancer Society (ACS), and colleagues wrote. In 2014, breast cancer death rates were 41 percent higher among black women than among white women in the United States, the researchers said. To learn more about this disparity, the investigators looked at information on more than 550,000 non-elderly women with early stage breast cancer. Black women were more likely to be uninsured ... Read more

Related support groups: Depo-Provera, Provera, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Anastrozole, Breast Cancer, Metastatic, Letrozole, Megestrol, Zoladex, Megace, Evista, Aromasin, Breast Cancer - Adjuvant, Casodex, Exemestane

More Women Choose Breast Reconstruction After Mastectomy

Posted 13 Oct 2017 by Drugs.com

FRIDAY, Oct. 13, 2017 – Over five years, the proportion of U.S. breast cancer patients opting for breast reconstruction after mastectomy grew by about two-thirds, a new government report shows. An analysis of patient data shows breast reconstruction followed 40 percent of breast-removal surgeries in 2014 – up from less than one-quarter in 2009, according to the U.S. Agency for Healthcare Research and Quality (AHRQ). Among age groups, women aged 65 and older accounted for the largest increase in breast reconstructive surgery – 140 percent. "This type of information is essential for policymakers and health systems seeking to keep pace with important trends in clinical care," Gopal Khanna, agency director, said in an AHRQ news release. The overall increase during the study period was 65 percent, researchers said. While reconstruction procedures increased in all insurance groups, the ... Read more

Related support groups: Surgery, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative

Page 1 2 3 4 5 6 7 8 9 10 Next

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer

Related Drug Support Groups

tamoxifen, Femara, letrozole, Herceptin, Taxol, paclitaxel, epirubicin, leuprolide, Nerlynx, view more... trastuzumab, Tamoxifen Hexal, Genox, Pharmorubicin RDF, Pharmorubicin PFS, Tamosin, Tamoxen, Soltamox, Nolvadex D, Tamofen, Emblon, Tamone, Nolvadex, Onxol, Ellence, neratinib, Ogivri